Researcher
Paul Cos
- Research Expertise:In vitro and in vivo biofilm assays, Integrated antimicrobial (bacteria, fungi, yeasts and parasites) screening and profiling of pure compounds and extracts, targeting redox homeostasis in mycobacteria
- Keywords:MICROBIOLOGY, BACTERIOLOGY, BIOFILMS, INFLAMMATION, Pharmacy and pharmacology
- Disciplines:Microbiology, Systems biology, Laboratory medicine
- Research techniques:In vitro and in vivo (pre-clinical) models of infectious diseases (bacteria and fungi), evaluation of drugs
- Users of research expertise:Pharmaceutical companies (big pharma, SME, spin-off), news agencies, journalists, government agencies, regulatory (EU) agencies, non-governmental organisations in the field of infectious diseases
Affiliations
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Responsible
From1 Oct 2020 → Today - Laboratory for Microbiology, Parasitology and Hygiene (LMPH) (Research group)
Member
From1 Oct 2006 → 30 Sep 2020
Projects
11 - 20 of 59
- The exploration of novel rapid technologies and alternatives to conventional microbiological test approaches (μRATE).From1 Apr 2020 → 31 Dec 2023Funding: VLAIO - research project companies
- RNA biomarkers discovery for ultra-fast drug synergy and susceptibility testing in the mycobacterium avium complex.From1 Jan 2020 → 31 Oct 2020Funding: BOF - doctoral mandates
- iMI-project - support - RespiriTB and RaspiriNTMFrom1 Jan 2020 → TodayFunding: IOF - technology concept exploration
- A platform to functionally assess clinically relevant respiratory parameters in small animal models for infectious and non-infectious pulmonary research.From1 Jan 2020 → 31 Dec 2021Funding: BOF - scientific equipment program
- Exploitation of key enzymes of the mycothiol biosynthesis to improve treatment of mycobacterium avium complex infections.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
- Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors (RespiriTB).From1 May 2019 → TodayFunding: H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and wellbeing
- Natural products and pharmaceutical services to improve the patient quality of life in Eastern Cuban Hospital's.From1 Jan 2019 → 31 Dec 2022Funding: VLIR-UOS Institutional University Cooperation Program (IUC)
- Development of a comprehensive platform for targeting redox homeostasis in Mycobacterium tuberculosis.From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Exploring the anti-inflammatory potential of Rothia mucilaginosa in chronic lung diseases.From1 Jan 2019 → 31 Dec 2022Funding: FWO research project (including WEAVE projects)
- Turning black into golden soldier fly larvae (Hermetia Illucens): added value creation by exploring its microbiota and metabolism (ETOBIOTA).From1 Jan 2019 → 31 Dec 2022Funding: FWO Strategic Basic Research (SBO)
Publications
1 - 10 of 272
- A high-throughput target-based screening approach for the identification and assessment of Mycobacterium tuberculosis mycothione reductase inhibitors(2024)
Authors: Natalia Smiejkowska, Lauren Oorts, Linda De Vooght, Rob Geens, Henri-Philippe Mattelaer, Koen Augustyns, Sergei V. Strelkov, Dirk Lamprecht, Koen Temmerman, Yann Sterckx, et al.
Pages: 1 - 22 - In vitro modelling of bacterial pneumonia(2024)
Authors: Laure Mahieu, Laurence Van Moll, Linda De Vooght, Peter Delputte, Paul Cos
Pages: 1 - 23 - All eyes on the prefusion-stabilized F construct, but are we missing the potential of alternative targets for respiratory syncytial virus vaccine design?(2024)
Authors: Lotte Jacobs, Kim Stobbelaar, Paul Cos, Peter Delputte
Pages: 1 - 27 - Bioinsecticide potential of ethanol extracts from Persea americana (Lauraceae) seeds on Aedes aegypti mosquitoes(2023)
Authors: Silvia Molina Bertrán, Idelsy Chil-Nunez, Julio Cesar Escalona-Arranz, Raimundo Nonato Picanco-Souto, Alejandro Felipe Gonzalez, Jesus Garcia Diaz, Paul Cos, Gabriel Llauradó Maury, Humberto Joaquin Morris-Quevedo
Pages: 404 - 414 - Selected strategies to fight pathogenic bacteria(2023)
Authors: Aiva Plotniece, Arkadij Sobolev, Claudiu T. Supuran, Fabrizio Carta, Fredrik Björkling, Henrik Franzyk, Jari Yli-Kauhaluoma, Koen Augustyns, Paul Cos, Linda De Vooght, et al.
Pages: 1 - 27 - Expanding the squaramide library as mycobacterial ATP synthase inhibitors(2023)
Authors: Jan Chasák, Lauren Oorts, Milan Dak, Veronika Šlachtová, Václav Bazgier, Karel Berka, Linda De Vooght, Natalia Smiejkowska, Laurence Van Moll, Davie Cappoen, et al.
Pages: 1 - 18 - Mycothione reductase as a potential target in the fight against Mycobacterium abscessus infections(2023)
Authors: Linda De Vooght, Y. Gansemans, F. Van Nieuwerburgh, Paul Cos
Pages: 1 - 14 - In vitro persistence level reflects In vivo antibiotic survival of natural Pseudomonas aeruginosa isolates in a murine lung infection model(2023)
Authors: Laure Verstraete, Juliana Aizawa Porto de Abreu, Matthias Govaerts, Linda De Vooght, Rob Lavigne, Jan Michiels, Bram van den Bergh, Paul Cos
Pages: 1 - 17 - Development and validation of a multiplex electrochemiluminescence immunoassay to evaluate dry eye disease in rat tear fluids(2023)
Authors: Agnese Compagnone, Linda De Vooght, Paul Cos
Pages: 1 - 15 - Acyloxymethyl and alkoxycarbonyloxymethyl prodrugs of a fosmidomycin surrogate as antimalarial and antibacterial agents(2023)
Authors: Charlotte Courtens, Frits van Charante, Thibaut Quennesson, Martijn Risseeuw, Paul Cos, Guy Caljon, Tom Coenye, Serge Van Calenbergh
Pages: 1 - 14
Patents
1 - 5 of 5
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- Compositions against candida infections (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)